Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
Open the sourceReported by MarketWatch, marketwatch.com, 9 November 2026
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Muhabbit only has the headline for this one. The full report is at marketwatch.com.